The 28 most recent market catalysts affecting $SMMT, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Sep 22, 2026
Corporate Catalyst
Neutral
Impact 65
Summit Therapeutics Notes That Data From The Phase III HARMONi-GI1 Trial Will Be Presented At The European Society For Medical Oncology Congress, October 23–27
Summit Therapeutics is highlighting the upcoming presentation of Phase III HARMONi-GI1 trial data at ESMO 2026. This matters because the trial, sponsored by Akeso, demonstrated sta…
Sep 15, 2026
Corporate Catalyst
Bullish
Impact 75
Summit Therapeutics Presents Updated Overall Survival Results From Global Phase III HARMIONi Clinical Trial Of Ivonescimab At The International Association For The Study Of Lung Cancer Conference; Sustained OS Improvement Seen With Longer Follow-Up In Western Patients, Consistent Across Geographic Regions; No New Safety Signals Observed
Summit Therapeutics announced updated overall survival data from its HARMONi Phase III trial for ivonescimab, a bispecific antibody for EGFR-mutated NSCLC. The key update is the su…
Sep 14, 2026
Corporate Catalyst
Bullish
Impact 85
Why Is Summit Therapeutics Stock Gaining Monday?
Summit Therapeutics' partner Akeso Inc. released compelling Phase 3 data for ivonescimab, demonstrating superior overall survival compared to Merck's pembrolizumab (Keytruda) in fi…
Sep 9, 2026
Corporate Catalyst
Bullish
Impact 75
Jefferies Upgrades Summit Therapeutics to Buy, Raises Price Target to $25
Jefferies analyst Faisal Khurshid upgraded Summit Therapeutics (SMMT) from a 'Hold' to a 'Buy' rating and significantly raised the price target from $15 to $25. This action indicat…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 85
Better Cancer Therapy Than Keytruda? Summit Therapeutics Partner's Ivonescimab Outperforms in Lung Cancer Study
Summit Therapeutics' shares are trading higher after its partner, Akeso Inc., announced that ivonescimab monotherapy showed statistically significant and clinically meaningful over…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 75
Summit Therapeutics, HUTCHMED, Tesla And Other Big Stocks Moving Higher On Thursday
The filing primarily highlights Summit Therapeutics' significant stock jump due to positive results from its Phase III HARMONi-2 study. This is a crucial development for a biotechn…
Sep 3, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics shares are trading higher after the company announced results from the randomized, double-blind Phase III HARMONi-2 study.
The positive Phase III HARMONi-2 study results for Summit Therapeutics are a major corporate catalyst, directly impacting the company's stock price. Successful late-stage clinical …
Sep 2, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics' Partner Akeso Announces Overall Survival Results From The Randomized, Double-Blind Phase III HARMONi-2 Study Evaluating Ivonescimab Monotherapy; Ivonescimab Monotherapy Demonstrated A Statistically Significant Improvement Compared To Pembrolizumab Monotherapy.
Summit Therapeutics' partner Akeso reported that ivonescimab monotherapy achieved a statistically significant improvement in overall survival compared to pembrolizumab monotherapy …
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics Partner Highlights Positive Interim Data Milestone for Lead Cancer Therapy
Summit Therapeutics' partner Akeso Inc. released positive topline findings from its Phase 3 HARMONi-GI1 clinical trial for ivonescimab, showing statistically significant and clinic…
Aug 26, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics shares are trading higher after the company announced topline results from the randomized Phase III HARMONi-GI1 study met the key secondary endpoints of progression-free survival and objective response rate.
This headline represents a major positive corporate catalyst for Summit Therapeutics. Successful Phase III trial results, especially meeting key secondary endpoints like progressio…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics' Partner Akeso Announces Topline Results From The Randomized Phase III HARMONi-GI1 Study Evaluating Ivonescimab Plus Chemotherapy Compared With Durvalumab Plus Chemotherapy As A First-line Treatment For Patients With Advanced Biliary Tract Cancer; Study Meets Key Secondary Endpoints Of PFS And ORR
Summit Therapeutics announced that its partner, Akeso Inc., reported positive topline results from the Phase III HARMONi-GI1 study for ivonescimab in advanced biliary tract cancer.…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics Says Ivonescimab Combination Extends Progression-Free Survival in Lung Cancer Patients
Summit Therapeutics' announcement of positive Phase 3 HARMONi trial results for ivonescimab is a significant development. The drug demonstrated a statistically significant improvem…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics shares are trading higher after the company announced the publication of primary analysis results from the global Phase III HARMONi clinical trial in The Lancet Oncology. Bernstein upgraded the stock from Underperform to Market Perform and raised its price target from $9.8 to $11.9.
This headline represents a significant corporate catalyst for Summit Therapeutics. The publication of primary analysis results from a global Phase III clinical trial in a highly re…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 65
Bernstein Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $11.9
Bernstein analyst Jeffrey Walch upgraded Summit Therapeutics (SMMT) from 'Underperform' to 'Market Perform' and raised the price target from $9.8 to $11.9. This upgrade signals a m…
Aug 25, 2026
Corporate Catalyst
Bullish
Impact 75
Summit Therapeutics Announces Publication Of Primary Analysis Results From Global Phase III HARMONi Clinical Trial In The Lancet Oncology
Summit Therapeutics announced the publication of the primary analysis results from its global Phase III HARMONi clinical trial in The Lancet Oncology. This is a significant event b…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 55
Leerink Partners Upgrades Summit Therapeutics to Market Perform, Raises Price Target to $13
Leerink Partners analyst Daina Graybosch upgraded Summit Therapeutics (SMMT) from an 'Underperform' rating to 'Market Perform' and simultaneously raised the price target from $12 t…
Aug 12, 2026
Corporate Catalyst
Bullish
Impact 75
Summit Therapeutics Says Partner Akeso Receives Third China NMPA Approval For Ivonescimab, Covering First-Line Advanced Squamous NSCLC With Chemotherapy
The third NMPA approval for Ivonescimab in China, specifically for first-line advanced squamous NSCLC with chemotherapy, is a significant positive for both Summit Therapeutics and …
Aug 5, 2026
Corporate Catalyst
Bullish
Impact 65
Summit Therapeutics Expands Its Clinical Development Program For Ivonescimab Into Urothelial Carcinoma An Orbladder Cancer, With The Initiation Of The Global, Multi-Regional Phase II/III HARMONi-GU1 Trial
Summit Therapeutics has announced the initiation of the HARMONi-GU1 trial, a global Phase II/III study for ivonescimab in urothelial carcinoma. This is significant because it expan…
Jul 24, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics Flags Going Concern Risk Over Cash Needs
Summit Therapeutics' 8-K filing reveals a critical 'going concern' warning, stating that its current cash reserves are inadequate for the next 12 months, despite raising over $299 …
Jul 24, 2026
Corporate Catalyst
Bearish
Impact 95
Summit Therapeutics shares are trading lower after the company reported Q2 financial results and disclosed it does not have sufficient working capital to fund planned operations for the next twelve months.
This headline represents a major corporate catalyst for Summit Therapeutics, indicating a severe financial distress that directly impacts its 'going concern' status. The lack of su…
Jul 23, 2026
Corporate Catalyst
Neutral
Impact 75
Summit Therapeutics Plans To Offer $380M Common Shares
Summit Therapeutics has filed an 8-K indicating its plan to offer $380 million in common shares. This is a significant capital raise for a company of its size, likely aimed at fund…
Jul 23, 2026
Corporate Catalyst
Bearish
Impact 95
Summit Therapeutics shares are trading lower after the company reported Q2 financial results and disclosed it does not have sufficient working capital to fund planned operations for the next twelve months.
This headline signals a severe corporate catalyst for Summit Therapeutics, indicating a significant financial distress. The disclosure of insufficient working capital to fund opera…
Jul 23, 2026
Corporate Catalyst
Bearish
Impact 95
Summit Therapeutics Raises Going Concern Doubt, Says Current Cash Is Insufficient To Fund Operations For The Next 12 Months
Summit Therapeutics has explicitly stated that its current financial resources are inadequate to sustain operations for the next year, leading to a 'going concern' qualification. T…
Jul 23, 2026
Corporate Catalyst
Bearish
Impact 92
Summit Therapeutics Q2 Adj. EPS $(0.19) Beats $(0.28) Estimate
Summit Therapeutics announced its Q2 adjusted EPS of $(0.19), which significantly beat the analyst consensus estimate of $(0.28). This indicates that the company's financial perfor…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics Says Extended Follow-Up Reveals Stronger Survival Advantages with lead Cancer Drug
Summit Therapeutics released updated overall survival data for its lead cancer drug, ivonescimab, from the Phase 3 HARMONi study. The extended follow-up revealed a stronger hazard …
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 92
Summit Therapeutics shares are trading higher after the company announced Phase III HARMONi clinical trial results.
The positive Phase III HARMONi clinical trial results for Summit Therapeutics are a major corporate catalyst, directly impacting the company's stock price positively. Successful Ph…
Jul 22, 2026
Corporate Catalyst
Bullish
Impact 85
Summit Therapeutics Reports Updated Overall Survival Data In Phase III HARMONi Trial Of Ivonescimab Plus Chemo Showing Improved OS Trend; PDUFA Goal Action Date November 14
Summit Therapeutics announced updated overall survival (OS) data from its Phase III HARMONi trial for ivonescimab, showing an improved hazard ratio of 0.76, consistent across Asian…
Jul 14, 2026
Corporate Catalyst
Bullish
Impact 65
Summit Therapeutics Signs Agreement With Biossil For Sale Of Ridinilazole, Investigational Phase III Precision Antibiotic Owned By Summit
Summit Therapeutics announced the sale of ridinilazole, an investigational Phase III antibiotic, to Biossil, Inc. This matters because ridinilazole previously failed to meet its pr…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.